Conclusion of non-exclusive agreements for medicinal products with the active ingredient Relugolix (ATC code: L02BX04) via an Open-House model
Original notice title
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Vereinbarungen über Arzneimittel mit dem Wirkstoff Relugolix (ATC-Code: L02BX04) im Wege eines Open-House-Modells
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
No guaranteed minimum quantities; actual demand is uncertain and may be low.
Buyer may terminate the Open-House model early if exclusive agreements are concluded (typically 8-12 months after publi...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Dec 31, 2027
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Dec 2027
- Supply of pharmaceutical products with active ingredient Relugolix (ATC L02BX04)
- Non-exclusive agreements with AOK PLUS for the region of Saxony and Thuringia, Germany
Show full summary
This tender is a non-exclusive Open-House model for pharmaceutical products containing Relugolix (ATC L02BX04). It allows any qualified pharmaceutical company to enter an agreement with AOK PLUS for supply to patients in Saxony and Thuringia, Germany. The notice is published for transparency but is not a formal EU procurement procedure. No estimated value is provided, and quantities are unknown. The agreement runs until 31 December 2027, with rolling submission deadlines starting 5 March 2026.
Risks
No guaranteed minimum quantities; actual demand is uncertain and may be low.
Buyer may terminate the Open-House model early if exclusive agreements are concluded (typically 8-12 months after publi...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical company as defined in §4(18) of the German Medicines Act (AMG)
Eligibility
- Must submit a self-declaration of no exclusion grounds (Eigenerklärung zum Nichtvorliegen von Ausschlussgründen)
Administrative
- Must submit a self-declaration regarding Russia sanctions (Eigenerklärung Russlandsanktionen)
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Conclusion of non-exclusive agreements for medicinal products with the active ingredient Relugolix (ATC code: L02BX04) via an Open-House model
Non-exclusive agreements for supply of Relugolix to AOK PLUS. No minimum quantities, no exclusivity. Open to all qualifying pharmaceutical companies during the participation period.
Location
Duration
Category
Award Criteria
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht-exklusiver Vereinbarungen über Arzneimittel mit dem Wirkstoff Relugolix (ATC-Code: L02BX04) im Wege eines Open-House-Modells
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 19 Feb 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 120686-2026
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
No guaranteed minimum quantities; actual demand is uncertain and may be low.
Buyer may terminate the Open-House model early if exclusive agreements are concluded (typically 8-12 months after publi...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications